drugset / Trial / NCT05696977

Effect of Obesity on Cyclosporine Blood Trough Level in Nephrotic Syndrome Patients

NCT05696977

Phase 4 Unknown 74 enrolled Alexandria University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study aims to assess the effect of obesity on therapeutic response and safety of cyclosporine trough level in nephrotic syndrome patients and calculating a suitable weight-based dose.

Timeline

Start
2022-04-17
Primary completion
2024-02
Completion
2024-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 3 mg/kg

Indications